Immune regulatory and neuroprotective properties of preimplantation factor: From newborn to adult.

Barnea, E R; Almogi-Hazan, O; Or, R; Müller, Martin; Ria, F; Weiss, L; Paidas, M J (2015). Immune regulatory and neuroprotective properties of preimplantation factor: From newborn to adult. Pharmacology & therapeutics, 156, pp. 10-25. Elsevier 10.1016/j.pharmthera.2015.10.008

[img] Text
1-s2.0-S0163725815002004-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Embryonic-maternal interaction from the earliest stages of gestation has a key, sustained role in neurologic development, persisting into adulthood. Early adverse events may be detrimental in adulthood. Protective factors present during gestation could significantly impact post-natal therapy. The role of PreImplantation Factor (PIF) within this context is herein examined. Secreted by viable early embryos, PIF establishes effective embryonic-maternal communication and exerts essential trophic and protective roles by reducing oxidative stress and protein misfolding and by blunting the nocive let-7 microRNA related pathway. PIF's effects on systemic immunity lead to comprehensive immune modulation, not immune suppression. We examine PIF's role in protecting embryos from adverse maternal environment, which can lead to neurological disorders that may only manifest post-nataly: Synthetic PIF successfully translates endogenous PIF features in both pregnant and non-pregnant clinically relevant models. Specifically PIF has neuroprotective effects in neonatal prematurity. In adult relapsing-remitting neuroinflammation, PIF reverses advanced paralysis while promoting neurogenesis. PIF reversed Mycobacterium smegmatis induced brain infection. In graft-vs.-host disease, PIF reduced skin ulceration, liver inflammation and colon ulceration while maintaining beneficial anti-cancer, graft-vs.-leukemia effect. Clinical-grade PIF has high-safety profile even at supraphysiological doses. The FDA awarded Fast-Track designation, and university-sponsored clinical trials for autoimmune disorder are ongoing. Altogether, PIF properties point to its determining regulatory role in immunity, inflammation and transplant acceptance. Specific plans for using PIF for the treatment of complex neurological disorders (ie. traumatic brain injury, progressive paralysis), including neuroprotection from newborn to adult, are presented.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology

UniBE Contributor:

Müller, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0163-7258

Publisher:

Elsevier

Language:

English

Submitter:

Monika Zehr

Date Deposited:

25 Feb 2016 10:34

Last Modified:

10 Nov 2016 17:58

Publisher DOI:

10.1016/j.pharmthera.2015.10.008

PubMed ID:

26546485

Uncontrolled Keywords:

Immune regulation; Neuroprotection; PreImplantation Factor (PIF)

BORIS DOI:

10.7892/boris.77693

URI:

https://boris.unibe.ch/id/eprint/77693

Actions (login required)

Edit item Edit item
Provide Feedback